Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.47 |
| ▸ | MAOB | P27338 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13178590 | 0.90 | NPC1 (0.51) | NPC1RAB9AMAPTCA12CA1 | |
| SCHEMBL12425216 | 0.90 | NPC1 (0.51) | NPC1RAB9AMAPTCA12CA1 | |
| SCHEMBL14421372 | 0.86 | LMNA (0.55) | NPC1RAB9AMAPTCA1CA2 | |
| SCHEMBL14421289 | 0.86 | PKM (0.63) | NPC1RAB9AMAPTCA1CA2 | |
| SCHEMBL17973760 | 0.84 | ACHE (0.48) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL8764585 | 0.84 | NPC1 (0.62) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL128091 | 0.84 | NPC1 (0.81) | NPC1RAB9AMAPTHRH3MAOB | |
| SCHEMBL14099148 | 0.83 | ALDH1A1 (0.74) | NPC1RAB9AMAPTCA1CA2 | |
| SCHEMBL6810964 | 0.83 | ALDH1A1 (0.51) | NPC1RAB9AMAPTCA12CA1 | |
| SCHEMBL779443 | 0.83 | NPC1 (0.58) | NPC1RAB9AMAPTHRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490291-B1 | LITHIUM SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION FOR USE IN THE LITHIUM SECONDARY BATTERY | UBE INDUSTRIES (JP) | 2014-12-03 | — | — | EP | claimed |
| EP-2490291-A1 | LITHIUM SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION FOR USE IN THE LITHIUM SECONDARY BATTERY | Ube Industries, Ltd. (JP) | 2012-08-22 | — | — | EP | claimed |
| US-20120183846-A1 | LITHIUM SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION FOR USE IN THE LITHIUM SECONDARY BATTERY | UBE INDUSTRIES, LTD. (JP) | 2012-07-19 | — | — | US | claimed |
| US-20250002435-A1 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-01-02 | — | — | US | disclosed |
| US-20240025849-A1 | INHIBITORS OF NO PRODUCTION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023241950-A1 | MIXTURES OF COMPOUNDS HAVING IMPROVED SOLUBILITY FOR USE AS MARKERS | BASF SE (DE) | 2023-12-21 | — | — | WO | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20200190099-A1 | NOVEL PYRIMIDINE DERIVATIVE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION PROCESS THEREOF, AND PHARMACEUTICAL COMPOSITION USING THE SAME | SPARK BIOPHARM, INC. (KR) | 2020-06-18 | — | — | US | disclosed |
| US-10618914-B2 | 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190100535-A1 | 6-ARYL-7-SUBSTITUTED-3-(1H-PYRAZOL-5-YL)-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AS INHIBITORS OF THE STAT3 PATHWAY WITH ANTI-PROLIFERATIVE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180210338-A1 | RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-4766241-A | LOWER ACUTE TOXICITY | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-23 | — | — | US | disclosed |
| EP-0275007-A2 | Process for the preparation of highly molecular, optionally branched polyarylene sulfides | BAYER AG (DE) | 1988-07-20 | — | — | EP | disclosed |
| CN-86104070-A | LIGHT-SENSITIVE SILVER HALIDE PHOTOGRAPHIC MATERIAL | — | 1986-12-24 | — | — | CN | disclosed |
| EP-0088345-B1 | 2-AMINOMETHYL-6-SULFAMOYLPHENOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-17 | — | — | EP | disclosed |
| US-4607030-A | ANTIEDEMICS, HYPOTENSIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-08-19 | — | — | US | disclosed |
| EP-0088346-B1 | 2-AMINOMETHYL-PHENOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-06-05 | — | — | EP | disclosed |
| EP-0088345-A2 | 2-Aminomethyl-6-sulfamoylphenol derivatives, process for their preparation, their use and pharmaceutical preparations based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
| EP-0088346-A2 | 2-Aminomethyl-phenol derivatives, process for their preparation, their use and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
| US-4246176-A | Synthesis of 5-aroyl-1-hydrocarbylpyrrole-2-acetic acid | ETHYL CORPORATION (US) | 1981-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002435-A1 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | CYP4F2, CYP4F8, CYP4F3 | NPC1 374/4885RAB9A 3525/4885MAPT 3596/4885 |
| US-20240025849-A1 | INHIBITORS OF NO PRODUCTION | NOS2, NOS1, NOS3 | NPC1 434/4885RAB9A 2105/4885MAPT 1147/4885 |
| US-20190100535-A1 | 6-ARYL-7-SUBSTITUTED-3-(1H-PYRAZOL-5-YL)-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AS INHIBITORS OF THE STAT3 PATHWAY WITH ANTI-PROLIFERATIVE ACTIVITY | STAT3, STAT1, STAT5A | NPC1 3995/4885RAB9A 3504/4885MAPT 4625/4885 |
| US-10618914-B2 | 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity | STAT3, STAT1, STAT5A | NPC1 3995/4885RAB9A 3504/4885MAPT 4625/4885 |
| US-20200190099-A1 | NOVEL PYRIMIDINE DERIVATIVE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION PROCESS THEREOF, AND PHARMACEUTICAL COMPOSITION USING THE SAME | DPYD, NUDT1, NUDT5 | NPC1 1457/4885RAB9A 1479/4885MAPT 2354/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | NPC1 518/4885RAB9A 2260/4885MAPT 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.